Or it is rather a demonstration of efficacy and social accountability?

ECONOMIST: Letters

Paul Wicks, a co-author of the paper, said social network-run studies may be most useful for testing efficacy of so-called off-label or off-patent compounds that patients are using but are unlikely to ever attract pharmaceutical company interest.

WSJ: ALS Study Falls Short, But Use of Social Media Holds Promise